Description
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,Western blot,
Mutation description:Knockout achieved by using CRISPR/Cas9, Homozygous: Insertion of the selection cassette in exon 1.,
Disease:Adenocarcinoma
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-TNFRSF10B, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Western blot, Zygosity-Homozygous, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
DR5 also known as Death Receptor 5 TRAIL-R2 or TNFRSF10B is a protein critical in apoptosis. It is a transmembrane receptor with a mass of approximately 54 kDa. Researchers find it expressed mostly in tissues such as lung colon and prostate. DR5 functions by binding to its ligand TRAIL triggering the extrinsic apoptotic pathway. Through this mechanism DR5 initiates a cascade of caspase activation that leads to cell death.
Biological function summary
DR5 plays a significant role in the regulation of apoptosis particularly in cancer cells. It is a component of the TRAIL receptor complex which includes several other death receptors like DR4. This complex formation allows DR5 to mediate apoptotic signals more efficiently. By controlling apoptosis DR5 helps maintain tissue homeostasis and prevents abnormal cell proliferation.
Pathways
DR5 is an important part of the TRAIL signaling pathway and the extrinsic apoptosis pathway. It connects with proteins like FADD and Caspase-8 essential in the apoptotic signaling cascade. By interacting with these proteins DR5 drives the progression of the apoptotic signal ensuring the removal of dysfunctional cells. Such pathways are vital for restraining tumor development and progression.
DR5 exhibits significant relevance to cancer and autoimmune diseases. Its ability to induce apoptosis through the TRAIL pathway keeps oncogenic transformations in check. In cancer DR5 often interfaces with other proteins like Bcl-2 which are involved in cell survival. Furthermore defects or aberrant expressions in DR5 have associations with autoimmune disorders where excessive cell death or survival contributes to disease pathology. DR5's role in these conditions makes it a promising target in therapeutic strategies.
